LCM
IMNM icon

Laurion Capital Management’s Immunome IMNM Stock Holding History

Laurion Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-102,954
Closed -$2.54M – 646
2024
Q1 		$2.54M Hold
102,954
– – 0.02% 323
2023
Q4 		$1.1M Buy
+102,954
New +$856K 0.01% 334

Other funds holding IMNM

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Laurion Capital Management's IMNM Position: Q2 2024 in Review

Laurion Capital Management sold out of Immunome (IMNM) in Q2 2024, closing a stake of 102,954 shares — an estimated $2.54M sold.

Laurion Capital Management first reported a position in IMNM in Q4 2023 and held it in 2 quarters. The position peaked at $2.54M in Q1 2024. 113 funds tracked by Wall St. Rank hold IMNM as of Q2 2024.

  • Laurion Capital Management reported no remaining Immunome position as of Q2 2024 after selling out during the quarter.
  • Laurion Capital Management sold 102,954 Immunome shares in Q2 2024, an estimated $2.54M.
  • Laurion Capital Management first reported a position in Immunome in Q4 2023 and held it in 2 quarters.
  • Laurion Capital Management's Immunome position peaked at $2.54M in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Immunome as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.